Market Overview - The medical device sector experienced a decline of 1.06% on November 19, with Caina Co., Ltd. leading the losses [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Top Gainers in Medical Device Sector - Zhonghong Medical (300981) saw a closing price of 15.09, with a gain of 10.39% and a trading volume of 285,000 shares, totaling a transaction value of 432 million yuan [1] - Dongfang Ocean (002086) closed at 2.98, up 9.96%, with a trading volume of 2.14 million shares and a transaction value of 620 million yuan [1] - Shuoshi Biology (688399) closed at 63.45, gaining 5.75% with a trading volume of 39,400 shares and a transaction value of 242 million yuan [1] Top Losers in Medical Device Sector - Caina Co., Ltd. (301122) closed at 27.54, down 5.88%, with a trading volume of 44,100 shares and a transaction value of 124 million yuan [2] - Tianyi Medical (301097) closed at 58.24, down 5.35%, with a trading volume of 17,500 shares and a transaction value of 102 million yuan [2] - Jimin Health (603222) closed at 10.22, down 4.58%, with a trading volume of 365,800 shares and a transaction value of 378 million yuan [2] Capital Flow Analysis - The medical device sector experienced a net outflow of 841 million yuan from institutional investors, while retail investors saw a net inflow of 875 million yuan [2][3] - The top net inflows from retail investors were observed in Dongfang Ocean (002086) with 2.37 million yuan, while Caina Co., Ltd. (301122) saw a net outflow of 12.38 million yuan from retail investors [3]

Group 1 - The core viewpoint of the news is the performance and market position of Zhonghong Medical, which saw a stock price increase of 5.78% to 14.46 CNY per share, with a total market capitalization of 6.201 billion CNY [1] - Zhonghong Medical specializes in the research, production, and sales of high-quality disposable protective gloves, with its main business revenue composition being 89.48% from health protection products, 6.22% from safety injection products, and 4.30% from innovative incubation products [1] - The company is located in the Luan Nan Economic Development Zone in Tangshan, Hebei Province, and was established on December 22, 2010, with its listing date on April 27, 2021 [1] Group 2 - From the perspective of major circulating shareholders, Yongying Fund has a fund that ranks among the top shareholders of Zhonghong Medical, while the Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 794,700 shares, which is 0.2% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 4.73 billion CNY, and has recorded a year-to-date return of 7.36% [2] - The fund manager of the Medical Device ETF is Shu Kefa, who has a total fund asset scale of 6.282 billion CNY, with the best fund return during his tenure being 103.17% and the worst being -30.27% [3]

Core Viewpoint - The company, Zhonghong Medical, is experiencing a decline in stock price and trading volume, with a focus on its international sales and innovative medical products in the veterinary sector [1][4]. Group 1: Company Overview - Zhonghong Medical specializes in the research, production, and sales of high-quality medical gloves and other medical consumables, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company was established on December 22, 2010, and went public on April 27, 2021, with its headquarters located in Tangshan, Hebei Province [9]. - As of September 30, 2025, the company reported a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [10]. Group 2: Market Position and Performance - The company has a significant international presence, with 81.56% of its revenue coming from overseas sales, benefiting from the depreciation of the Chinese yuan [4]. - Zhonghong Medical is classified as a state-owned enterprise, with its ultimate control held by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - The stock has seen a net outflow of 4.8682 million yuan today, with a lack of clear trends in major shareholder movements, indicating a dispersed ownership structure [6][7]. Group 3: Product Innovation and Development - The company emphasizes innovation and digital technology integration in product development, aiming to provide high-performance medical products that meet diverse market needs [3]. - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its veterinary infusion pumps, which received positive feedback for their safety and multifunctionality [2].

（文章来源：证券日报） 证券日报网讯 11月17日晚间，中红医疗发布公告称，本次保荐代表人更换后，公司IPO项目持续督导保 荐代表人为葛龙龙先生、雷浩先生。 ...

（文章来源：证券日报） 证券日报网讯 11月17日晚间，中红医疗发布公告称，同意聘任邓伟先生为公司第四届董事会的董事会 秘书。 ...

简历显示，邓伟1989年出生，历任华源证券股份有限公司投资银行部高级经理、国泰海通证券股份有限 公司投资银行部高级经理、副总裁、高级副总裁。 中红医疗表示，11月17日，公司召开了第四届董事会第十四次会议，审议通过了《关于聘任董事会秘书 的议案》，经公司薪酬考核与提名委员会审查通过后，同意聘任邓伟为公司第四届董事会的董事会秘 书，上述任期自本次董事会审议通过之日起至第四届董事会任期结束之日止，邓伟长期从事资本市场相 关工作，具备董事会秘书履职能力。 北京商报讯(记者丁宁)11月17日晚间，中红医疗（300981）发布公告称，公司董事会于近日收到公司董 事会秘书张琳波提交的书面辞职报告，因个人原因，张琳波申请辞去公司董事会秘书等职务，根据相关 规定，张琳波的辞职报告自送达董事会之日起生效。张琳波辞去公司董事会秘书等职务后，不再担任公 司及下属子公司任何职务。 ...

每经AI快讯，中红医疗（SZ 300981，收盘价：14.02元）11月17日晚间发布公告称，公司第四届第十四 次董事会会议于2025年11月17日以通讯方式召开。会议审议了《关于聘任董事会秘书的议案》等文件。 2025年1至6月份，中红医疗的营业收入构成为：医疗器械行业占比100.0%。 截至发稿，中红医疗市值为60亿元。 （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经头条（nbdtoutiao）——展望"十五五" | 专访尹艳林：让有钱且愿消费的人顺利消费；个税起征点可 提高，最高边际税率可下调，让有关群体少缴税、多收入 ...

每经头条（nbdtoutiao）——展望"十五五" | 专访尹艳林：让有钱且愿消费的人顺利消费；个税起征点可 提高，最高边际税率可下调，让有关群体少缴税、多收入 每经AI快讯，中红医疗（SZ 300981，收盘价：14.02元）11月17日晚间发布公告称，因个人原因，张琳 波先生申请辞去公司董事会秘书等职务，不再担任公司及下属子公司任何职务。张琳波先生辞去公司董 事会秘书等职务后，不再担任公司及下属子公司任何职务。公司审议通过了《关于聘任董事会秘书的议 案》，同意聘任邓伟先生为公司第四届董事会的董事会秘书。 2025年1至6月份，中红医疗的营业收入构成为：医疗器械行业占比100.0%。 截至发稿，中红医疗市值为60亿元。 （记者 张明双） ...

中红普林医疗用品股份有限公司（以下简称"公司"）于近日收到公司首次 公开发行股票并在创业板上市的保荐机构国泰海通证券股份有限公司（以下简称 "国泰海通证券"）出具的《国泰海通证券股份有限公司关于更换中红普林医疗 用品股份有限公司持续督导保荐代表人的函》，由于原保荐代表人邓伟先生因工 作变动原因，无法继续从事公司的持续督导工作，为保证持续督导工作的有序进 行，国泰海通证券现委派保荐代表人葛龙龙先生接替邓伟先生继续履行持续督导 工作，保荐代表人葛龙龙先生简历详见附件。 证券代码：300981 证券简称：中红医疗 公告编号：2025-102 中红普林医疗用品股份有限公司 关于更换持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 二〇二五年十一月十七日 附件： 保荐代表人葛龙龙先生简历 葛龙龙先生，男，中国国籍，现任国泰海通证券投资银行部高级副总裁，保 荐代表人。2015 年起从事投资银行业务，曾负责或参与益诺思 IPO、之江生物 IPO、中红医疗 IPO、起帆电缆 IPO、森麒麟轮胎 IPO、东方材料 IPO、界龙实业 增发、世茂股份增发、天 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-101 中红普林医疗用品股份有限公司 关于董事会秘书辞职及聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会秘书辞职情况 上市公司董事会秘书培训证明，在取得上市公司董事会秘书培训证明前，董事会 指定邓伟先生代行董事会秘书职责，待邓伟先生取得董事会秘书资格证书后，正 式履行董事会秘书职责。 邓伟先生联系方式如下： 特此公告 中红普林医疗用品股份有限公司 董事会 二〇二五年十一月十七日 中红普林医疗用品股份有限公司（以下简称"公司"）董事会于近日收到公 司董事会秘书张琳波先生提交的书面辞职报告，因个人原因，张琳波先生申请辞 去公司董事会秘书等职务，根据相关规定，张琳波先生的辞职报告自送达董事会 之日起生效。张琳波先生辞去公司董事会秘书等职务后，不再担任公司及下属子 公司任何职务。 张琳波先生担任董事会秘书的原定任期为 2024 年 7 月 15 日至 2027 年 7 月 15 日。截至本公告日，张琳波先生未直接或间接持有公司股份，不存在应当履 行而未履行的承诺事项。公司 ...